Author/Authors :
Suthar, Krishna H. Department of Internal Medicine - University of Texas Medical Branch, USA , Kesireddy, Meghana Department of Internal Medicine - University of Texas Medical Branch, USA , Sides, Mark Department of Internal Medicine - Division of Hematology and Medical Oncology - University of Texas Medical Branch, USA , Correa, Amit Department of Internal Medicine - Division of Hematology and Medical Oncology - University of Texas Medical Branch, USA , Ukudeyva, Aijan Department of Pathology - University of Texas Medical Branch, USA , Venkatesan, Rohit Division of Medical Oncology - MD Anderson Cancer Center, USA
Abstract :
Squamous cell carcinoma (SCC) of the urethra is a rare malignancy, comprising less than 1% of all malignancies. The annual age-adjusted incidence of urethral SCC is 4.3 per million in men and 1.5 per million in women. Due to the rarity of the disease, there area limited number of prospective randomized controlled trials to evaluate the optimal management of locally advanced urethralSCC. Here, we present the case of a 47-year-old man with stage IIIB urethral squamous cell cancer that showed completeclinical and pathologic response to neoadjuvant chemoradiation with only 5-flurouracil after incomplete response to traditionalchemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP).
Keywords :
Neoadjuvant Radiation , Concurrent 5-FU Resulting , Complete Pathologic Response , Stage IIIB Squamous Cell Carcinoma , Urethra , SCC , TIP
